Objectives: To evaluate the ability of body-weight-driven renal function assessment (RFA) formulae to predict on-target elimination rate ranges for gentamicin in patients with varying degrees of renal function.
Introduction
For empirical dosing of renally adjusted drugs, patient demographics and laboratory characteristics are often relied upon to select the ideal dose and interval extension. The ultimate goal for the clinician is to engineer similar drug concentration exposures across a wide variety of clinical populations such as the elderly, those with extremes of body weight and those with reduced renal function. For the past 40 years the latter has been attempted through variations on the Cockcroft-Gault formula for CL CR assessment. 1 More recently, however, there has been a general rethinking of the design of the renal function assessment (RFA) formula to improve upon its accuracy and uniformity across populations. 2, 3 One issue was the most appropriate body weight to use within the formula, i.e. whether total body weight (TBW), lean body weight (LBW), ideal body weight (IBW) or an obesity-corrected dosing weight should be used. In response to the lack of consensus on which body weight to use, Brown et al. 2 proposed that the answer must lie somewhere in between TBW and an IBW, thus suggesting a functional 'range of potential CL CR values' to assist with dosing interval selection. Although interesting, it is a much more imprecise solution to the problem. Ahern and Possidente 4 called for an investigation to identify the best weight or normalized-weight-based RFA formula to predict serum drug concentrations, but in the interim suggested a non-weight-based approach for reasons which will be discussed below. They recommended using a 72 kg weightnormalized CL CR formula as a reasonable option going forward.
For most renally eliminated drugs, some derivation of body weight is typically used to select the ideal dose, whereas renal function is employed to help guide dosing interval selection. Therefore, the focus of research should be on finding the RFA formula that most accurately reflects the ideal dosing interval for therapeutic drug concentrations. In fact, Ryzner 5 suggested that future studies should be based on using actual drug concentrations and pharmacokinetic parameters, thus avoiding the literature's latest 'gold standard' comparators. The intent of our V C The Author 2017. Published by Oxford University Press on behalf of the British Society for Antimicrobial Chemotherapy. All rights reserved. For Permissions, please email: journals.permissions@oup.com. J Antimicrob Chemother 2017; 72: 1802-1811 doi:10.1093/jac/dkx036 Advance Access publication 27 March 2017 research was to address this clinically important question using actual drug concentrations as the goal.
Our novel approach to the problem was to characterize the ideal dosing interval based on an elimination rate associated with a literature historic peak of 8 mg/L and a trough between 0.5 and 2 mg/L for various dosing interval extensions. Knowing that elimination rate could vary acceptably within this range of desired concentrations, we sought to identify which formula would best correspond with on-target elimination rates for optimal peak and trough concentrations. We examined each patient's measured elimination rate from our retrospective population and then compared it with their laboratory creatinine levels and demographically derived RFA formulae. We developed a method to discern which formula selected the most appropriate elimination rate and thus the optimal dosing interval extension.
Our objective was to evaluate the relative performance of the various RFA formulae at achieving on-target elimination rates associated with attaining traditional therapeutic range serum concentrations of gentamicin.
Patients and methods
We conducted a single-centre, retrospective study of adult patients receiving gentamicin at a university teaching hospital from stored pharmacokinetic research data collected between 1990 and 1995. We included only patients 18 years of age and older who had received at least one dose of intravenous gentamicin for surgical prophylaxis, or treatment on a medical-surgical unit or within a medical-surgical ICU. 
Study design
The study included 103 patients involving 147 data sets of gentamicin serum concentrations. Patient pharmacy records were examined for: (i) patient demographics (gender, age, creatinine, weight and height); (ii) documentation of all gentamicin doses, intervals and infusion times; and (iii) records of all sampling times for at least two serum gentamicin concentrations. Peak concentrations were measured at least 30 min after the end of the infusion.
Gentamicin pharmacokinetic parameters were individually determined for each assessment date from two or three measured concentrations. The non-linear least-squares fitting routine found within the ADAPT-5 pharmacokinetic modelling software was used assuming a one-compartment open model with first-order drug elimination. 6 Using ADAPT-5 software allowed for the non-assumption of steady-state conditions. For patients with more than one pharmacokinetic assessment, earlier sets of concentrations were removed from subsequent analyses so as not to influence future model fitting with physiological conditions that may have changed.
Gentamicin serum concentrations were analysed by fluorescence polarization immunoassay (TDx; Abbott Diagnostics). The overall error pattern of the gentamicin assay was determined by fitting a second-order polynomial to the assay's standard deviation (SD) versus serum concentration profile:
, where C is the gentamicin concentration. The SDs were obtained from the laboratory as identified for their low, mid-range and high gentamicin concentration assessments from that time period. Using the ADAPT fitting routine, each concentration was weighted to the reciprocal of its assay error variance (i.e. 1/SD 2 ). The patient's gentamicin elimination rate constant (k el ) and volume of drug distribution (V) were determined for each assessment time. An assay error variance model allowed for better control of the assay error variability of the measured gentamicin concentrations.
In 2009, laboratories throughout North America adopted a new creatinine assay using an isotope dilution mass spectrometry (IDMS) method instead of the colorimetric Jaffe reaction. 7, 8 The older conventional method overestimated creatinine (i.e. creatinine concentrations falsely elevated by up to 20%), because of the detection of non-creatinine chromagens. Although the new assay provided consistent results with a high degree of precision, it also resulted in discrepant creatinine concentrations that are 5%-20% lower than the previous method. 8 In order to compare the performances of the various formulae to current-day reported creatinine values, the older creatinine values during this study were recalibrated using the method described by Jones et al. 8 ( Figure 1 ).
The various RFA formulae shown in Figure 1 were compared with the gentamicin k el s uniquely identified for each patient from their measured gentamicin concentrations. Most RFA methods involved substituting TBW, IBW, LBW or a normalized 72 kg body weight (NBW) into the CockcroftGault formula. Other methods used were the Modification in Diet Renal Disease (MDRD) equation 14 and Sanford's method. 13 The Sanford method is based on Sanford's Guide 13 which uses IBW for non-obese individuals and then a Salazar-Corcoran-based 16 weight substitution for obese individuals. In addition, we utilized a locally modified NBW* method (mNBW*), which involved multiplying NBW* by 90% in order to account for an approximate 10% lower creatinine value. The 10% lower creatinine value was selected at our institution as an average reduction after assay method recalibration in 2009. The use of the asterisk here on weight methods denotes the CL CR formula using that body weight method. Demographic data were reported as mean + SD ( Table 1 ). The Freedman-Diaconis rule was used to calculate bin-width for histogram plots of total body weights across the population studied as h " 2 % IQR % n
#1/3
, where h is the bin width and n is the number of samples studied. 17 Suggested gentamicin dosing interval extensions based on traditional desired peaks of 8 mg/L and troughs of 1 mg/L were used for the intervals of every 6 h, three-times daily, twice daily and once daily ( Table 2) . 18 The peak of 8 mg/L has a known pharmacokinetic/pharmacodynamic basis in that if a conservative susceptible MIC was 1 mg/L for a serious Gramnegative organism, optimally we would want to achieve at least a peak/ MIC ratio of 8/1 for the best clinical cure. [19] [20] [21] [22] A range for k el was then generated for trough results varying from 0.5 to 2 mg/L as being acceptable. Note that conservatively some overlap was allowed for the k el s between dosing intervals based on the attainment of traditional therapeutic goals for gentamicin. For example, given Table 2 and the associated intervals with respect to k el , a three-times daily dosing interval would have been found appropriate for a k el value of 0.1733 h #1 (as the trough would be acceptable at 1.99 mg/L); and a twice-daily dosing interval would have been found appropriate for a k el of 0.2310 h #1 (as the trough would be acceptable at 0.5 mg/L). Thus, if a k el generated fell between 0.1733 and 0.2310, it would be considered acceptably on target for any one formula to select either a three-times daily or twice daily interval for that patient. The upper and lower limits on some intervals conservatively overlapped for a given RFA level. This was more evident at higher RFA levels in Table 2 . In addition, a modification to the dosing tables was made in order to allow for the clinically relevant every 6 h regimen 23 using the same concentration targets.
An instantaneous bolus was used to remove the influence of renal function on drug elimination during the infusion. The results of this analysis are shown in Table 2 and their respective formulae for each of the dosing intervals are: . Body weights, recalibrated creatinines and renal function assessment formulae. IBW, ideal body weight; LBW2005, lean body weight, the 2005 version from reference 10; BSA, body surface area; TBW, total body weight. TBW* and IBW* are creatinine clearances as assessed using total body weight and ideal body weight in those formulae, respectively. MDRD is the MDRD-4 equation; however, laboratories report this as an estimated glomerular filtration rate (eGFR) and do not adjust for African-American status, leaving it to the clinician to decide when to apply it. NBW* and mNBW* are CL CR s as assessed using a normalized body weight formula assuming a 72 kg average patient. The mNBW* formula incorporates an additional adjustment for the 2009 creatinine reagent change and thus a 90% numerator multiplication of the NBW* calculation. LBW2005* is the CL CR as assessed using the LBW calculation as above. If the lean weight exceeded the TBW, then the TBW was selected for that formula.
The various formulae were tested for agreement on interval selection relative to the best on-target formula using McNemar testing for paired proportions, and false discovery rate analysis for multiple comparisons. 24 All statistical analyses were two-tailed and results were considered significant at P , 0.05. Correlations among the seven RFA methods with respect to gentamicin elimination rates were also examined by regression analysis with a Pearson linear correlation and a coefficient of determination generated.
Results

Demographics and pharmacokinetic assessments
Eighty-five patients met the study inclusion criteria; approximately one-half (53%) of these patients were from a medical-surgical unit. Of the 147 individual pharmacokinetic assessments reviewed, 20 were excluded because of missing demographic and creatinine information. Some patients had repeated gentamicin assessments with more than one pair of pharmacokinetic parameter results. Thus, a total of 127 concentration-time events were studied, each generating a unique k el . Two assessments from the same patient were performed on 11.0% (14) , three assessments on 2.4% (3), four assessments on 0.8% (1) and finally five assessments on 0.8% (1) of the concentration-time events. Table 1 summarizes the patient demographics. Although creatinine varied between 0.41 and 4.29 mg/dL, the various RFA formulae had on average only 5% of calculated clearance values ,30 mL/min/RFA units. Of all pairs of pharmacokinetic parameters, 48% (61) were from patients 80 kg TBW. Thus, 80 kg was chosen as the cutoff to analyse the formula's ability to achieve on-target elimination rates for patients with larger body weights. Figure 2 displays the median, range and distribution of TBWs studied.
Renal function formula analysis
The coefficients of determination (R 2 ) between the RFA methods and gentamicin elimination rate found the best correlations with the mNBW*, NBW*, MDRD and IBW* methods at 35%, 35%, 32% and 28%, respectively, while the remaining methods had the poorest correlation with gentamicin elimination, i.e. Sanford's, LBW2005* and TBW* methods at 18%, 18% and 12%, respectively. Thus, 35% of the variability in drug elimination could be explained best by the mNBW* and NBW* methods. Figure 3 (a) illustrates the output for all RFA methods with respect to selecting the best elimination rate for the level of renal function. The mNBW* method had the highest on-target value overall of 72.4%, while the LBW2005* formula performed the worst (53.5%). Compared with mNBW*, dosing interval selection agreement was significantly lower for all other methods. Figure 3 (b) demonstrates greater differences in those with 80 kg TBW in favour of the mNBW* method, which was on-target in 80.3% of cases and again outperformed all other methods. When comparing formulae, 'overdosing' potential occurred almost twice as frequently with the NBW* method (21.3%) versus the mNBW* method (10.2%) (P " 0.04, Figure 3a) .
We also identified that on-target elimination rates improved to 76.9% for the critically ill versus 71.3% in the non-critically ill using the best-performing method (i.e. mNBW*). However, as this was Patient body weight on renal function assessment JAC only represented in 22 data-pairs from 11 patients, we had insufficient numbers to do an adequate statistical analysis.
To examine the influence of extreme body weight on these calculated RFA methods the results for a single 245 kg, 65 year old male patient in our data set were examined (the last data point on the far right in Figure 2 ). The measured k el was 0.235 h #1 and Table 2 shows correspondence with a three-times daily dosing interval and an RFA range of 60-119.9 (mL/min/RFA units). The Sanford and TBW* methods overestimated renal function at 141 and 239 mL/ min, respectively, and selection of an every 6 h regimen would have been inappropriate.
Discussion
Our results demonstrate that any RFA formula incorporating a body weight element offered the poorest on-target selection of elimination rates for gentamicin (Figure 3a and b) . We chose to compare the various methods against Sanford's Guide recommendations. 13 This guide, the most widely accepted and distributed infectious diseases manual, incorporates an IBW in the RFA formula, but in addition uses a Salazar-Corcoran adjustment for obesity. 16 For those smaller individuals weighing 60 kg the Sanford method simply defaults to the IBW method. The RFA formula using a normalized body weight of 72 kg and a formula reagent adjustment factor of 90% (mNBW*) provided the best on-target elimination rate predictions (72.4%) as compared with the LBW2005*, TBW* and NBW* formulae; and supported relatively low rates of overdosing (10.2%) and under-dosing (17.3%) as compared with other methods (Figure 3a) . Some have suggested that an adjusted or dosing body weight (DBW) should be utilized in the formula instead. One adjustment is a DBW with the TBW minus the IBW times 40% and added back to the IBW. 25 A post hoc analysis of this method showed that it performed just as poorly as the TBW* method at 66.1%, though with slightly fewer over-dosing recommendations (17.3% versus 19.7%), and slightly more underdosing recommendations (16.5% versus 14.2%).
Since the recalibration of creatinine concentrations by North American laboratories, failure to correct the formula with a numerator multiplication of 90% resulted in slightly fewer on-target predictions (72.4% versus 66.9%, P , 0.0001; mNBW* and NBW*, respectively; Figure 3a ), though the difference became even greater for patients with TBWs exceeding 80 kg (80.3% versus 72.1%, P , 0.0001; mNBW* and NBW*, respectively; Figure 3b ). Additionally, mNBW* was still superior to all other RFA methods when analysed for those exceeding 80 kg TBW (Figure 3b ). The LBW2005* method was trialled in our research, since Janmahasatian et al. 26 had suggested that this weight was best for normalizing the Cockcroft-Gault formula for obese individuals in order to render the normalized value in 'mL/min/kg' the same for obese and non-obese individuals. They concluded that their normalizing formula for lean body mass appears to explain the 'apparent' differences between obese and non-obese patients. As can be seen in Figure 3 (b), LBW2005* was less likely to overestimate elimination when compared to TBW* (11.5% versus 27.9%, P , 0.0001) in heavier patients; however, it was still inferior in terms of identifying on-target elimination rates compared with the NBW* methods.
We were not the first to consider adjusting for, or re-expressing the RFA formula in order to account for, the change in the creatinine assay method. 8, [27] [28] [29] The most recent MDRD formula has in fact been re-expressed to conform to the change to the new IDMS assay. 28 In our research, we have analysed it using this clinically current, re-expressed format ( Table 1 ). The initial factor of 186 found within the original MDRD equation has been lowered to 175 (i.e. a 94% rule). 28 Some authors have suggested that this re-expression of the MDRD equation will allow for a consistent interpretation of the estimated glomerular filtration rate (eGFR) over the years, 29 but surprisingly this concept of formula re-expression has never been widely adopted for drug dosing. An excellent overview on RFA formula implications with the new creatinine assay standard can be found within Wade and Spruill's review. 29 Some clinicians have suggested doing nothing to the RFA formula or Ariano et al.
creatinine value as these probably have negligible influence on drug dosing. As we have seen from our results in Figure 3 , this was not the case for NBW* as compared with the re-expressed mNBW* formula. Fundamental to our results, Bauer et al. 30 found that for patients with similar degrees of renal function, the t1 =2 of aminoglycosides in both normal weight and morbidly obese patients was the same at about 2 h. They concluded that if t1 =2 was the same for both groups, then the dosing interval (e.g. three-times daily) should be the same irrespective of the body weight; however, the dose would simply have to be larger because of the greater distribution space relative to the increased body size in order to attain similar steady-state peak concentrations. The key take-home message this suggests is that if we are seeking the elimination rate associated with any degree of renal function, body weight should never be part of that formula. Other investigators have found similar results with elimination rate being unchanged with increasing body weight for a number of drugs. In these cases there is an absolute, but non-proportional, increase in both V and CL with increasing body weight for those with similar degrees of renal function. Figure 3 . (a) All formula relative to the method providing for the highest percentage of cases with on-target elimination rates (i.e. mNBW*) as represented by the dashed lines (n " 127). All P , 0.0001 relative to mNBW* corrected with false discovery rate analysis. The top dotted area represents the probability of selection of an elimination rate associated with too frequent dosing; while the bottom dotted area represents the probability of selection of elimination rates associated with a too infrequent dosing. (b) These were all formulae for only patients 80 kg TBW relative to the formula with the highest percentage cases with on-target elimination rates (i.e. mNBW*) as represented by the dashed lines (n " 61). All P , 0.0001 relative to mNBW* corrected with false discovery rate analysis. The top dotted area represents the probability of selecting an elimination rate associated with too frequent dosing; while the bottom dotted area represents the probability of selecting elimination rates associated with too infrequent dosing.
Patient body weight on renal function assessment JAC A number of authors have reported on this non-linear increase in drug distribution space 31 and drug clearance with obesity. 32, 33 Since k el is simply the ratio of these non-proportionally, increasing parameters (i.e. as k el " CL/V), then the elimination rate should remain relatively unchanged for larger-body-weight individuals. Thus, as described by Bauer et al., 30 there is no net change in t 1/2 in the morbidly obese at least for aminoglycosides. This non-proportionality relationship is probably dependent on the ratio of fat mass to muscle mass and the lipophilic nature of the drug to some extent. Additional scientific support for no change in elimination rate of a drug at the upper extremes of body weight (i.e. obesity) is evident for ceftaroline, 34 daptomycin, 35, 36 ertapenem, 37 piperacillin/tazobactam, 38 ciprofloxacin, 39 enoxaparin, 40 bisoprolol, 41 atracurium, 42 digoxin 43 and glimepiride, 44 to name a few. One exception to this has been with the non-renally adjusted benzodiazepines, for which the elimination t 1/2 has been reported to lengthen in obesity. [45] [46] [47] Vancomycin has shown conflicting results as evident from a small study (n " 31) by Adane et al. 48 reporting a body-weight-dependent elimination rate with a longer t 1/2 corresponding to larger-body-weight patients. Unfortunately their study design utilizing a one-compartment pharmacokinetic model drew peak concentrations 'within' the 1 h distribution phase for vancomycin 48 and thus was susceptible to greater error in parameter identification. Contrast this with Bauer et al.'s 49 small study (n " 24) in which they found a shorter t 1/2 with larger-body-weight patients. A definitive study by Ducharme et al. 50 in 704 patients conversely identified that there was no significant change in elimination rate with vancomycin across body weight distributions.
Clinicians generally apply their RFA formula in order to achieve target serum concentrations. This is what Ryzner 5 is referring to when she suggests that future studies to assess the best RFA formula should be based on actual drug concentrations. On balance, the Cockcroft-Gault formula was historically generated using TBW in the formula when applied within the research setting to define dosage interval development. However, with normal Gaussian distribution and a lower incidence of obesity back in 1976, 32 body weight distributions would have tended to have fallen largely between 60 and 90 kg, and thus differences in body weight may not have had a very significant influence on dosage interval extension. It is only when one examines the influence of placing a much higher weight within the formula that one finds its erroneous divergence from selecting on-target elimination rates (e.g. as seen with the TBW* method results, Figure 3a and b) . Interestingly, Cockcroft and Gault stated that 'by chance the number [72] is in the denominator', thereby reducing their formula to simply the difference in patient age from 140, divided by serum creatinine, 1 and therefore did not realize that their regression had actually identified all CL CR results in 'mL/min' for all body weights as the ratio of that patient's weight to the population average body weight of 72 kg. For body weights close to the population average, this is probably appropriate in order to derive the 'mL/min' value.
Over the years, while seeking the best predictor formula for renal dosing adjustment, a number of investigators have had very divergent opinions on what should be considered the goldstandard comparator and have lost sight of what is truly important, namely therapeutic drug concentrations. Some study designs, e.g. have recommended a 24 h urine collection for CL CR as the gold standard and compared their measured result in 'mL/ min' to their tested RFA formula. 55 Others have chosen urinary clearance of iodine-125-iothalamate as their measure of GFR, but then chose to compare its clearance and formula performance as solely 'mL/min', 56 while still others re-expressed that same marker in terms of body surface area normalization as 'mL/min/1.73 m 2 '. 57 All of these designs suggested different solutions for the best formula, and left the reader without a clear answer for drug dosing.
Our goal should be to identify the elimination rate of the drug in question that corresponds to the level of creatinine, age and gender unique to that patient. The search for the best predictor formula should not be based upon its performance in predicting a patient's 24 h urine for CL CR ; 25, [51] [52] [53] [54] nor on trying to identify that patient's exact GFR; [56] [57] [58] [59] nor even on being able to predict their unique drug clearance in L/h. 5, 59 Some of these authors have justified their analysis by performing Bland-Altman plots to examine the degree of agreement between the tested formula and their perceived gold standard. The weakness with these plots is the overriding assumption that if an error occurs it must solely reside within the new formula being tested. There is actually no evidence that GFR or 24 h urines for CL CR optimally identify the dosing interval extension for any drug and thus these should never be considered as gold-standard comparators. Our research makes no assumptions with respect to a gold-standard RFA formula other than to state that 'this is the range in drug concentrations for any one dosing interval that we hope to achieve'.
Finding the exact GFR is important for physiological assessment and prognostication; however, dosing interval selections were never made with an exact GFR, or even a 24 h urine for the CL CR result. Even though endogenous creatinine undergoes tubular secretion as well as filtration and aminoglycosides only filtration, dosing interval extensions were based on this original construct which utilized CL CR in average-body-weight individuals. Our research has clearly demonstrated the inferior performance of using body weight or any of its derivations within a RFA formula (i.e. Sanford's, TBW*, IBW* or LBW2005* methods) to assess the elimination rate for the renally excreted drug gentamicin. And yet common downloadable cellphone 'apps' for CL CR assessment utilize 'total body weight' in their renal function calculation formula; a practice which, based on our findings for gentamicin, would certainly result in excessive drug exposure.
Comparisons of various CL CR formulae for predicting gentamicin elimination rates were first examined by Reichley et al. 60 Their approach of using a 72 kg average body weight is the same as our NBW* formula before the recalibration of creatinine measurements by laboratories. Their approach was slightly different than our own in that they and Bookstaver et al. 59 used the Dettli equation, 61 k el " 0.0024 % CL CR ! 0.01 to predict the k el s from the various inputted RFA formula and then compare those to measured k el s in their patients. We chose not to make any assumptions about the relationship between RFA and k el with a Dettli-style equation, but instead used standard historic therapeutic drug monitoring goals to focus on the most desired k el s. Intuitively our approach seemed most logical as it closely mirrored how the drug would be used in clinical practice and demanded the fewest assumptions. Our search was for the formula which best assists with selecting Ariano et al.
the right dosing interval for a drug given that patient's level of renal function.
RFA formulae have many derivations to estimate dosing alterations in those with reduced renal function. The widespread introduction of the National Kidney Disease Education programme's MDRD equation has seen a desire amongst clinicians and some authors to use this formula for drug dosing beyond its original role as a tool for staging chronic kidney disease. 62 This is a concern that was strongly echoed by others, as the formula has never been validated for drug dosing. 63, 64 In fact the MDRD is calculated automatically in many institutions and is thus very easy to refer to. It is important to note that African-American status within the formula is never calculated automatically outside the research setting. 28 Therefore, race was not included in our analysis in order to reflect what clinicians would actually see. We have chosen to include the MDRD in our analysis specifically to address its relative performance in the context of gentamicin dosing. Our results clearly confirm the lack of superiority of the MDRD in selecting the ideal elimination rate.
Limitations within our analysis include its retrospective nature and the fact that some patients had more than one pharmacokinetic assessment for comparison. We cannot see a scenario, however, in which multiple assessments within our study design would somehow bias one formula over another. In addition, and since this is the first known study design of its kind, we had no way of doing a priori power calculations for sample size. Data collection and numbers utilized were all based on available archived patient pharmacokinetic research records. Importantly other researchers in this area have reported smaller study designs, with Bookstaver et al. 59 utilizing 71 patients and Demirovic et al. 25 examining only 54 patients. In addition, although mNBW* was found to be superior to NBW* (i.e. accounting for the creatinine reagent change), we did not test whether the other renal function methods would have improved if they had also incorporated a reagent adjustment with that 90% rule. As a reagent correction factor is not the usual practice with the Cockcroft-Gault formula in the clinical community for TBW*, IBW*, LBW2005* or Sanford's method, we have therefore chosen to leave them unaltered for our analysis. Wolowich and Steinberg 27 have demonstrated that a modification of the current creatinine by a 20% increase within their TBW* CL CR formula significantly improved their prediction of aminoglycoside t 1/2 . This would be equivalent to a numerator multiplication factor of 83% of our NBW* formula, rather than the 90% as we had tested with mNBW*. They studied TBW within their RFA, but excluded obese patients defined as TBW exceeding IBW by 1.3 times. We do not know if their lower multiplication factor of 83% would have improved our results even more. Another limitation is that we did not have many patients with severe renal dysfunction (Table 1 ; 5%), commonly referred to as chronic kidney disease (CKD) stages 4 and 5, i.e. calculated values of ,30 mL/min/units. Part of the strength in our analysis lay in the selection of a very diverse clinical population of general-medical, surgical prophylactic and critically ill medical-surgical patients, as well as in a wide range of ages, body weights and renal function. Although body weight is not important for dosing interval selection, other work has shown its importance for selecting the 'size of the dose'. D'Angio et al. 15 summarized this situation best back in 1988 when they argued that body weight should never be part of the formula when assessing drug dosing interval adjustments; an opinion reflected by others over the years. 4, 64 Our data clearly support this contention by demonstrating that on-target elimination rates for gentamicin with the mNBW* formula resulted in the best performance. Finally, there is a concern that this approach only applies to gentamicin. The literature demonstrates that for other renally eliminated drugs, elimination rate is unchanged in obesity; thus, this paper acts as a proof of concept for the avoidance of body weight derivations within RFA formula by pharmacists. We look forward to its further validation with many other renally adjusted drugs. We propose that researchers and pharmaceutical companies should in future utilize this simple and accurate mNBW* formula within clinical trials on renal drug dosing adjustments.
Body weight should never be utilized within a CL CR formula to assess renal dosing adjustments irrespective of the extremes of patient body weight. Sanford's, IBW* and the MDRD method did not improve upon selection of the ideal dosing interval extension in those with renal dysfunction for the drug gentamicin. The RFA formula of mNBW* assuming a normalized body weight of 72 kg resulted in the best on-target elimination rate assessment amongst all the methods tested. Calculated CL CR results with the mNBW* format for renal drug dosing should be reported as 'mL/min/72 kg'.
